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 24 
ABSTRACT 25 
Human noroviruses (NoVs) are the main etiological agents of acute gastroenteritis 26 
worldwide. While NoVs are highly diverse (more than 30 genotypes have been 27 
detected in humans), during the last 40 years most outbreaks and epidemics have been 28 
caused by GII.4 genotype strains, raising questions about their persistence in the 29 
population. Among other potential explanations, immune evasion is considered to be 30 
a main driver for their success. In order to study antibody recognition and evasion in 31 
detail, we have analyzed a conformational epitope recognized by a monoclonal 32 
antibody (3C3G3) by phage display, site-directed mutagenesis and surface plasmon 33 
resonance. Our results show that the predicted epitope is composed of eleven amino 34 
acids within the P domain: P245, E247, I389, Q390, R397, R435, G443, Y444, P445, 35 
N446, and D448. Only two of them, R397 and D448, differ from the homologous 36 
variant (GII.4 Den-Haag_2006b) and from a previous variant (GII.4 VA387_1996) 37 
which is not recognized by the antibody. A double mutant derived from the 38 
VA387_1996 variant containing both changes Q396R and N447D is recognized by 39 
the 3C3G3 monoclonal antibody, confirming the participation of these two sites in the 40 
epitope recognized by this antibody. Furthermore, a single change, Q396R, is able to 41 
modify the HBGA recognition pattern. These results provide evidence that the epitope 42 
recognized by the 3C3G3 antibody is involved in the virus-host interactions both at 43 
the immunological, as well as at the receptor levels. 44 
KEY WORDS: Norovirus, GII.4 genotype, epitope, monoclonal antibody, virus-host 45 
interaction, viral variant, antibody escape, receptor46 
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 47 
IMPORTANCE 48 
Human noroviruses are the main cause of viral diarrhea worldwide in people of all 49 
ages. Noroviruses can infect individuals who had been previously exposed to the 50 
same or different norovirus genotypes. Norovirus genotype GII.4 has been reported to 51 
be the most prevalent during the last 40 years. In the present study, we describe a 52 
novel viral epitope identified by a monoclonal antibody and located within the highly 53 
diverse P domain of the capsid protein. The evolution of this epitope along sequential 54 
GII.4 variants has allowed noroviruses to evade previously elicited antibodies, thus 55 
explaining how the GII.4 genotype can persist over long periods, re-infecting the 56 
population. Our results also show that this epitope participates in the recognition of 57 
host receptors which have evolved over time as well. 58 
 59 
60 
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INTRODUCTION 61 
Noroviruses (NoVs) are the predominant etiological agents of acute gastroenteritis 62 
worldwide, causing both outbreaks and sporadic cases (1-3). NoVs have become in 63 
many countries the main cause of infantile gastroenteritis since the introduction of 64 
rotavirus vaccines (4-7), and they have also been recognized globally as the main 65 
cause of associated foodborne diseases (8, 9).  66 
NoVs belong to the Caliciviridae family, and currently they are classified into 6 67 
genogroups (GI-GVI) (10) subdivided into more than 30 genotypes based on the 68 
capsid protein  sequence diversity. That notwithstanding, most human NoV infections 69 
are caused by genogroups GI and GII. Furthermore, in the last two decades genotype 70 
GII.4 has been the causative agent of >95% of NoV gastroenteritis outbreaks, with 71 
globally distributed epidemic viral variants emerging every 2-3 years (11, 12). 72 
NoVs are small non-enveloped viruses with a non-segmented single-stranded 73 
positive-sense RNA genome, which encodes the viral structural and non-structural 74 
proteins in three open reading frames (ORFs). ORF1 encodes the six non-structural 75 
proteins, including the viral protease and the RNA-dependent RNA polymerase 76 
(RdRp), while ORF3 encodes a small basic protein, VP2, which interacts with the 77 
VP1 and stabilizes the virion (13). ORF2 encodes the major structural protein VP1, 78 
which is further organized into the N-terminal (N), the shell (S), and the protruding 79 
(P) domains. The P domain can be further divided into two subdomains, P1 and P2 80 
(14). The P1 subdomain forms the anchoring portion of the P dimer, connecting it to 81 
the S domain and promoting the stability of the viral particle, while the P2 subdomain 82 
is exposed on the surface of the capsid protein and is the most variable region of the 83 
virus (11). Both the main epitopes for immunorecognition, as well as the histo-blood 84 
group antigen (HBGA) binding domains, reside within this P2 subdomain. The 85 
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emergence and accumulation of mutations along the P2 subdomain is the main driver 86 
of evolution for GII.4 strains, and results in new epidemic strains with altered 87 
antigenicity and HBGA binding properties (15-18).  88 
GII.4 genotypes associated with the majority of NoV pandemics have been GII.4 89 
US1995_1996, Farmington_Hills_2002, GII.4 Hunter_2004, GII.4  Den Haag_2006b, 90 
GII.4 New Orleans_2009, and most recently GII.4 Sydney_2012. Of these six 91 
pandemic strains, it has been postulated that the first four are the result of the 92 
mutational evolution of the P domain capsid, whereas the two most recent variants 93 
display additional recombination events between ORF1 and ORF2 (12, 19). 94 
Despite recent advances in norovirus culture in vitro (20), the historical lack of an in 95 
vivo model (which mimics the disease) and of a reproducible in vitro replication 96 
system have hampered the study of NoVs including a definitive explanation to the 97 
evolutionary success of GII.4 strains. Despite these challenges, several alternatives 98 
and surrogate systems have been successfully applied to the study of the 99 
immunogenicity and receptor binding properties of NoV strains and their variants. 100 
Virus-like particle (VLP) expressed in mammalian or insect cells (21) and P particles 101 
expressed in E. coli (22) show similar structural properties to the native virus, 102 
maintain the antigenic properties and HBGA binding ability, and their use has led to 103 
the identification of several epitopes and HBGA binding domains (15, 23-26). 104 
In order to further characterize the impact of NoV GII.4 evolution on immune 105 
evasion, we analyzed the functionality of the epitope recognized by a monoclonal 106 
antibody (3C3G3) directed against a NoV GII.4 strain, using phage display and site-107 
directed mutagenesis. The epitope recognized is composed of eleven amino acids, two 108 
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of them, R397 and D448, being implicated in the folding of the epitope and in the 109 
recognition patterns for different HBGAs. 110 
 111 
MATERIALS AND METHODS 112 
Expression and purification of norovirus virus-like particles (NoV VLPs) 113 
VLPs of NoV strains GI.1 Norwalk, GII.3, GII.4_1999 (v0), GII.4_2004 (v2) and 114 
GII.4 Den Haag_2006b were expressed in insect cells after infection with 115 
recombinant baculoviruses, as previously described (15). 116 
 117 
Expression and purification of recombinant NoVs P particles and P domains  118 
P particles from NoV GI.1 Norwalk strain, GII.9 VA207 strain and GII.4 variants 119 
VA387_1996, Den Haag_2006b and Sydney_2012, as well as five mutants of the 120 
VA387_1996 variant (M1 to M5, see below) were produced and purified in E. coli 121 
BL21 as previously described (27). GII.9 VA207 synthetic gene was purchased as a 122 
synthetic gene (GeneArt, Invitrogen). The Den Haag_2006b P particle was subcloned 123 
from a previous VP1 construction available in our laboratory (28) using the primers 124 
P524 and P590 previously described (22), and the GII.4 Sydney_2012 variant was 125 
cloned from a clinical sample using P-Sydney forward 126 
(5’GCACGGATCCTCAAGAACTAAACCATTCTCTG3’) and reverse 127 
(5’GCATGCGGCCGCTTAGCAAAAGCAATCGCCACGGCAATCGCATACTGC128 
ACGTCTACGCCCCGTTCC3’) primers. The P domain of the GII.4 Apeldoorn_2007 129 
strain was also produced and purified as previously described (28). This construction 130 
is referred to as P domain and not P particle because it lacks the cysteine rich peptide 131 
that stabilizes the formation of P particles. 132 
 o
n
 July 13, 2016 by University of Liverpool Library
http://jvi.asm.org/
D
ow
nloaded from
 
7 
 
After the affinity chromatography step 10 mM EDTA was added to the resulting P 133 
particles to chelate the co-eluted nickel and loaded into a preparative HiPrep 16/60 134 
Sephacryl S-300 HR size exclusion chromatography column (GE Healthcare Life 135 
Sciences, Uppsala, Sweden) equilibrated with PBS. The fractions corresponding to 136 
the P particles (molecular weights between 750 and 1,100 kDa) were pulled and 137 
stored at -20ºC in PBS containing 10% glycerol. 138 
 139 
Antibodies utilized in the present study 140 
A newly developed monoclonal antibody (3C3G3 mAb) was obtained by immunizing 141 
a six-week-old female BALB/c mouse with NoV VLPs from GII.4 Den Haag_2006b 142 
via intraperitoneal injection with Freund’s adjuvant. Three days after the final boost 143 
injection, mouse spleen lymphocytes were fused with Sp2/0-Ag14 myeloma cells and 144 
hybridomas were screened by ELISA and subcloned by limiting dilution. One of the 145 
growing hybridomas produced an anti-GII.4_2006b VLP mAb (3C3G3) which was 146 
purified using HiTrap protein A sepharose columns (GE Healthcare). Two previously 147 
obtained and characterized monoclonal antibodies were also used in the present study: 148 
the anti-v0.8 mAb raised against the pre-epidemic GII.4 v0_2000 variant, and the 149 
anti-v2.5 mAb raised against the GII.4 v2_2004 variant (15). Two polyclonal antisera 150 
were also utilized in the present study. These were obtained by immunizing rabbits 151 
following standard methods, either with GII4 VA387_1996 P particles (P-pAb) or 152 
with a mixture of VLPs GII.4 v0_2000, GII.4 v2_2004 and GII.3 (HPA-pAb). 153 
 154 
Characterization of antibodies by ELISA  155 
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The 96-well microtiter plates (Corning, NY) were coated with the different VLP 156 
variants, P particles or P domain (see above) at 1 µg/ml in carbonate/bicarbonate 157 
buffer (pH 9.2) and incubated overnight at 4ºC. Plates were blocked by incubating 1 h 158 
at 37ºC in PBS 0.05% Tween (PBST) with 3% BSA. The primary antibodies (anti-159 
v0.8 mAb, anti-v2.5 mAb, 3C3G3 mAb, P-pAb and HPA-pAb were added to the 160 
coated plates at two fold dilutions starting at 1/1,000 until 1/128,000 dilution in PBST 161 
containing 1% BSA. Binding was detected with either HRP-conjugated anti-mouse 162 
IgG at 1/4,000 or anti-rabbit IgG at the same dilution (Santa Cruz Biotechnology) as 163 
appropriate. The reactions were developed by the addition of OPD (o-164 
phenylenediamine dihydrochloride, Sigma) and stopped after 10 min of incubation 165 
with 3 M H2SO4. Absorbance was measured at 492 nm in a microplate reader 166 
Multiskan Spectrum (Thermo Fisher Scientific, Vantaa, Finland). Assays were 167 
performed in triplicate and negative and blank controls were included. The mean 168 
value of negative controls (without primary antibody) plus 3 SDs was used as the cut-169 
off value. 170 
Saliva binding blocking assay  171 
Microtiter plates (Corning, NY) were coated with saliva from one secretor positive 172 
donor diluted 1/500 in carbonate/bicarbonate buffer (pH 9.2), and incubated 37ºC for 173 
1 h and at 4ºC overnight. Plates were washed three times with PBST and blocked with 174 
PBS containing 3% BSA for 1 h at 37ºC. The GII.4 2006b P particles (1 µg/ml) were 175 
incubated 1 h with serial dilutions of the 3C3G3 mAb in PBST at 37ºC. The mixture 176 
was added to the coated plate and incubated for 1 h at 37ºC. After three washes, the P-177 
pAb was added at a dilution of 1/1,000. Finally, a HRP-conjugated anti-rabbit at 178 
1/4,000 (Santa Cruz Biotechnology) was added. The OPD substrate was used to 179 
develop the reactions that were stopped after a 20 min by adding 3 M H2SO4. The 180 
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absorbance was measured at 492 nm. Assays were performed in triplicate and the 181 
blocking of the binding was expressed as percentages of signal referred to the 182 
negative blocking control OD492 (P particles without any blocking agent). 183 
 184 
3C3G3-epitope characterization by phage display  185 
Ph.D.-C7C Phage Display Peptide Libraries (1.5x1013 plaque forming units (pfu)/ml) 186 
and the host bacterial strain E. coli ER2738 were purchased from New England 187 
Biolabs (Beverly, MA, USA). 188 
Panning was carried out in 96-well microtiter plates by direct target coating, mainly 189 
referenced from the Ph.D.-C7C library kit manual. Briefly, purified 3C3G3 mAb 190 
(100 µg/ml) was coated on a 96-well plate with 150 μl of carbonate buffer (0.1M 191 
NaHCO3, pH 8.6) and incubated overnight at 4°C under gentle agitation. Nonspecific 192 
binding was blocked by incubation with 300 μl of blocking buffer (NaHCO3 0’1 M 193 
pH 8’6 containing BSA at 5 mg/ml) for 1 h at 4°C. For the panning–elution 194 
procedure, approximately 2 × 1011 pfu/ml phages diluted with 0.1% TBST were 195 
incubated with the 3C3G3-coated plate for 45 min at room temperature with shaking. 196 
Unbound phages were removed by washing with 0.01% TBST. The 3C3G3 mAb-197 
bound phages were eluted with 100 μl of glycine (0.2 M glycine-HCl, pH 2.2) 198 
containing 1 mg/ml of BSA and then neutralized with 15 μl of Tris-HCl 1 M pH 9.1. 199 
The eluted phages were amplified and purified to be used for subsequent rounds of 200 
selection and to infect E. coli ER2738 for amplification and titration. In the second 201 
and third rounds of panning, the stringency of washing was augmented by increasing 202 
the number of washes and the amount of Tween-20, in consecutive rounds. 203 
After three rounds of panning–elution selection, individual positive clones were 204 
picked up from LB/IPTG/Xgal plates, amplified and submitted for DNA sequencing. 205 
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The primer used for sequencing was 96gIII (5′-CCCTCATAGTTAGCGTAACG-3′), 206 
provided by the kit. The sequences coding 7 amino acids were identified and used to 207 
predict the epitope.  208 
 209 
Epitope modeling  210 
Conformational modeling of the epitope was carried out using the Pepitope server 211 
(29). The crystal structure of the NoV GII.4 VA387_1996 strain was used as the 212 
model to localize the epitope recognized by mAb 3C3G3 (PDB id: 2OBR). The 213 
Modeller (http://salilab.org/modeller/) program (version 9.15) was used for homology 214 
and comparative modeling of three-dimensional protein structures (30). We used the 215 
GII.4 VA387_1996 strain structure as the template (PDB id: 2OBR) and provided an 216 
adequate alignment with the sequences of the different mutants M1 to M5 (see 217 
below). The Modeller software built the required number of models of the target and 218 
estimated the quality parameters of the models. The model with the best dope score 219 
was chosen for each mutant. The structures were visualized with the Pymol (The 220 
PyMol Molecular Graphics System, Version 0.99, Schrodinger, LLC) program. 221 
 222 
Site-directed mutagenesis 223 
To confirm the amino acid residues forming part of the 3C3G3 epitope, the GII.4 224 
VA387_1996 strain (not recognized by the antibody) was used as a scaffold to 225 
incorporate the amino acids present in the predicted epitope. Five mutants were 226 
constructed by introducing the following mutations into the GII.4 VA387_1996 227 
sequence: M1 (Q396R); M2 (N447D); M3 (NN- 393, 394 STT); M4 (M1+M2); and 228 
M5 (M1+M2+M3) (Figure 1). The GeneArt site-directed mutagenesis system 229 
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(Thermo Fisher) was applied following the manufacturer’s instructions to incorporate 230 
the mutations. The primers utilized to create the mutants are listed in Table 1. M1 and 231 
M2 were produced in one step, but M3 was constructed in two steps using first the 232 
MUT_3_1_FW and MUT_3_1_RV primers and then the MUT_3_2_FW and 233 
MUT_3_2_RV in a second mutagenesis reaction. The M4 construction (double 234 
mutant incorporating M1 and M2) was made using the M1 construction as the 235 
template and incorporating the M2 mutation afterwards. To create the M5 mutant, the 236 
M3 construction was used as template using primers MUT_1_3_FW and 237 
MUT_1_3_RV to incorporate M1 without changing the M3 mutation that was already 238 
present, followed by the addition of the M2 mutation.  239 
Transformants were analyzed by PCR and sequencing. Positive transformants were 240 
transferred to the E.coli BL21 strain GroES/EL and mutant P particles were produced 241 
and purified as previously described (27). 242 
 243 
Surface plasmon resonance (SPR) 244 
The binding ability of P particles (GII.4 VA387_1996, M1, M2, M3, M4, M5 and 245 
Den Haag_2006b) to three different mAbs (3C3G3, anti-V0.8 and anti-V2.5) was 246 
tested by Surface Plasmon Resonance (SPR) using a Biacore T100 instrument 247 
(Biacore, GE Healthcare). An anti-His antibody (Clontech) was immobilized on the 248 
surface of CM5 chips (GE Healthcare) and used as a capture antibody for P particles. 249 
Immobilization was achieved using the Amine Coupling Kit (GE Healthcare). Briefly, 250 
5000 anti-His mAb resonance units (RU) were immobilized in channel 2 leaving 251 
channel 1 as a reference. Each P particle was captured flowing a solution of 100 252 
µg/ml for 100 seconds at a flow rate of 5 µl/min in HBS-EP+ buffer (GE Healthcare) 253 
to reach a capture level of ~100 RUs. Several dilutions of each mAb (100 nM, 50 nM, 254 
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25 nM, 12.5 nM and 6.125 nM) were injected, starting with the most dilute and 255 
finishing with the most concentrated one, on the CM5 chip at a flow rate of 30 µl/min 256 
in HBS-EP+ buffer (GE Healthcare) at 25ºC in single cycle kinetics experiments. The 257 
binding time was 60 seconds with final dissociation time of 600 seconds. Each 258 
interaction was tested in three independent experiments. Binding and kinetics 259 
evaluations were performed with the Biacore Evaluation Software. 260 
 261 
P particle binding to neoglycoconjugates 262 
The binding of P particles to five different neoglycoproteins (Table 2) with the 263 
oligosaccharide structure of antigen H (blood group O), of blood group A, blood 264 
group B, Lewis X (Lex) and Sialyl Lewis X (SiLex) was assayed by ELISA. All the 265 
neoglycoproteins were obtained from Isosep AB (Tullinge, Sweden). The 266 
oligosaccharides were linked to human serum albumin (HSA), through an 267 
acetylphenylenediamine (APD) or aminophenylethyl (APE) spacer, with 10–30 268 
oligosaccharides per protein molecule.  269 
Microtiter plates (Corning, NY) were coated with the different neoglycoconjugates at 270 
1 µg/ml in carbonate/bicarbonate buffer (pH 9.2), and incubated 37ºC for 1 h and at 271 
4ºC overnight. Plates were washed three times with PBST and blocked with PBS 272 
containing 3% BSA for 1 h at 37ºC. The P particles were added at 1 µg/ml in PBST 273 
and the plates were incubated 90 min at 37ºC. After three washes, the P-pAb was 274 
added to the plates at a dilution of 1/1,000. Binding was detected with HRP-275 
conjugated anti-rabbit at 1/ 4,000 (Santa Cruz Biotechnology). The reactions were 276 
developed by the addition of OPD and stopped after a 20 min incubation with 3 M 277 
H2SO4. Absorbance was measured at 492 nm. Assays were performed in triplicate and 278 
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negative (non-functionalized HSA at 1 µg/ml), and blank controls were included. The 279 
binding was expressed as percentages of signal referred to the higher OD492.  280 
Ethics statement 281 
In this study, Balb/c mice were employed to obtain monoclonal antibodies. The 282 
Animal Welfare and Ethics Committee of the University of Valencia approved all the 283 
protocols conducted here, according to applicable national and international 284 
guidelines. JB possesses the accreditation by the Conselleria de Agricultura, 285 
Generalitat Valenciana, to design and perform experiments with laboratory animals.  286 
287 
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RESULTS  288 
Production and purification of norovirus P particles 289 
With the aim to study the immunogenicity and binding ability of different NoV strains 290 
to several HBGAs a total of ten P particles were produced, one corresponding to the 291 
GI.1 Norwalk genotype, four corresponding to different GII NoVs (GII.9 VA207 292 
strain, GII4 VA387_1996 strain,  GII.4 Den Haag_2006b strain and GII4 293 
Sydney_2012 strain), and the remaining obtained by site-directed mutagenesis of the 294 
GII.4 VA387_1996 P particle (M1 to M5). All the proteins showed a molecular 295 
weight close to the expected one (36 kDa), but with small differences. The GII4 296 
VA387_1996 variant showed a typical duplet band for this strain (22, 27). This duplet 297 
was also present in the M1 (Q396R) mutant. The M2 mutant (N447D) migrated as a 298 
single band, as well as did all the other constructions, except the M4 double mutant 299 
that displayed a lower mobility in the gel (Figure 2). The P particles were further 300 
purified by size exclusion chromatography. The results showed that the majority 301 
(more than 80%) of the produced proteins formed particles as it can be observed in 302 
Figure 3. The elution time was slightly different for every preparation ranging from 303 
37.89 ml (M1) to 40.29 ml (VA387) that corresponds to 1,030 kDa to 870 kDa 304 
(Figure 3). All together we were able to produce and purify ten different P particles 305 
that were used in ELISA, SPR and binding assays. 306 
 307 
Characterization of mAb by ELISA 308 
In order to elucidate the reactivity patterns of each one of the mAbs against different 309 
NoV genogroups, genotypes and variants the initial characterization of mAbs 3C3G3, 310 
anti-v0.8 and anti-v2.5 was performed by ELISA using a set of NoV antigens (Table 3 311 
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and Figure 4). As a control, the HPA-pAb was utilized. The 3C3G3 antibody 312 
recognized only its homologous VLP (GII.4 Den Haag_2006b) and the most closely 313 
related GII.4 Apeldoorn_2007 P domain. Surprisingly, it did not recognize the GII.4 314 
v2_2004 VLPs and GII.4 VA387_1996 P particle, two different variants within the 315 
same genotype. This result is similar to those obtained with the anti-v0.8 and anti-v2.5 316 
mAbs. The anti-v0.8 efficiently recognized its homologous GII.4 v0_1999 VLP and 317 
the GII.4 VA387_1996 P particle while the anti-v2.5 recognized only its homologous 318 
GII.4 v2_2004 VLP and the closer GII.4 2006b antigen, but not the GII.4 319 
Apeldoorn_2007 P domain. The HPA polyclonal antibody was able to recognize all 320 
the tested antigens except the GI.1 P particles (Table 3). These results confirm that the 321 
fast evolution of NoV GII.4 variants seem to be driven by the antibody pressure in the 322 
host, favoring the emergence of antibody escape variants.  323 
 324 
The 3C3G3 mAb blocks the binding of P particles to saliva 325 
The main aim of the present study was to characterize the epitope of a mAb directed 326 
to the viral capsid protein to give an explanation on how antibody evasion occurs in 327 
NoV GII.4 variants. It was important to know if the 3C3G3 mAb was able to block 328 
the binding of NoV to its receptors. For this reason a saliva binding blocking assay 329 
was performed, and the results confirmed that the 3C3G3 mAb is able to block the 330 
binding of GII.4 Den Haag_2006b P particles in a dose dependent manner to secretor 331 
positive saliva (Figure 5).  332 
 333 
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Characterization of the 3C3G3 mAb epitope by phage display and site-directed 334 
mutagenesis 335 
Aiming to characterize the epitope recognized by the 3C3G3 mAb the phage display 336 
technique followed by site-directed mutagenesis were applied. After three rounds of 337 
panning, a consensus sequence of 11 amino acids was obtained. The predicted epitope 338 
was formed by the following amino acids: P245, E247, I389, Q390, R397, R435, 339 
G443, Y444, P445, N446, and D448 of the GII.4 Den Haag_2006 variant (Figure 1). 340 
Three of these amino acids are within the P2 subdomain (I389, Q390, R397), and the 341 
other eight are within the P1 subdomain (Figure 6).  342 
To confirm the epitope, site-directed mutagenesis was performed using the P particle 343 
of GII.4 VA387_1996 variant as a scaffold. This variant was not recognized by the 344 
3C3G3 mAb, and only two residues were different among both proteins in the 345 
predicted epitope R397 and D448 (Figure 1). Five mutants were produced as 346 
described in the Material and Methods section (M1 (Q396R); M2 (N447D); M3 (NN- 347 
393, 394 STT); M4 (M1+M2) and M5 (M1+M2+M3)), and the reactivity of the 348 
3C3G3 mAb against the mutants was tested by ELISA. In addition to the mutants, two 349 
new P particles were added to the experiment: The GII.4 Den Haag_2006 variant P 350 
particles as the positive control and the GII.4 Sydney_2012 variant P particles to 351 
evaluate the performance of the antibody towards the newer GII.4 epidemic variant. 352 
The ELISA results, summarized in Table 3 and Figure 7A, found that none of the 353 
single mutants M1, M2, or M3 were recognized by the antibody. Interestingly, both 354 
the double mutant M4 and the multiple mutant M5 were recognized by the antibody, 355 
thus confirming that at least R397 and D447 form part of the epitope recognized by 356 
the 3C3G3 antibody. These results show that the antigenic site B (STT 393,394,395) 357 
does not seem to be involved in the formation of the 3C3G3 epitope, since M3 was 358 
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not recognized by the 3C3G3 mAb. It is also interesting that the later epidemic variant 359 
GII.4 Sydney_2012 is not recognized by the mAb while it shares the 11 residues of 360 
the predicted epitope (Table 4). This indicates that other residues not identified in this 361 
study might be implicated in the formation of the 3C3G3 epitope.  362 
To know if this novel described epitope affects the binding of other GII.4 directed 363 
mAbs the reactivity of anti-v0.8 and anti-v2.5 mAbs against the different P particles 364 
was also assayed by ELISA. The results show that the anti-v2.5 epitope might be 365 
different from the 3C3G3 epitope since none of the mutants were recognized by this 366 
mAb (Figure 7B). Interestingly this antibody was also independent from the 367 
previously described antigenic site B present here in M3 and M5 constructions (15). 368 
In contrast, the anti-v0.8 mAb reacted against each of the mutants, albeit at different 369 
levels. This may indicate that the selected residues exert an influence on the folding of 370 
the epitope recognized by this antibody since both mutagenized residues are 371 
conserved in VA387_1996 and V0_1999 variants (Table 4). According to our results 372 
this mAb showed a dependence on the antigenic B site as previously described (15). 373 
 374 
Characterization of the 3C3G3 mAb-epitope by surface plasmon resonance 375 
To quantify the interaction strength between the tested mAbs and the different P 376 
particles recognized by them, a surface plasmon resonance (SPR) approach was 377 
applied and affinity constants (KD) were obtained in at least three independent 378 
experiments. Of all the interaction pairs, the highest affinity (lowest KD value) was 379 
obtained in the 3C3G3- GII4 Deen Hag_2006b interaction pair (Table 3 and Figure 380 
8). Although M4 gave higher signal in ELISA (Figure 7A), the SPR experiments 381 
revealed that the M4 mutant had 6 times higher KD (153 nM) than M5 mutant did (25 382 
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nM) (Table 3). After modeling the structure of the different mutants, using the P 383 
domain of VA387_1996 structure as a scaffold (PDB id: 2OBR), we observed that the 384 
R397 and the D448 residues probably present different conformations in M4 and M5 385 
(Figures 3C and D). The M5 model had the D448 anionic carboxylate (RCOO−) and 386 
R397 cationic ammonium (RNH3+) closer. This increased the possibility of a saline 387 
bridge formation that permitted the 3C3G3 epitope stabilization. 388 
 389 
R397 is involved in HBGAs recognition 390 
The binding of the VA387_1996, Den Haag_2006b and Sydney_2012 variants, as 391 
well as of the five mutants (M1 to M5) to five different HBGAs (SiLex, Lex, blood 392 
group O (H antigen), blood group A and blood group B) was analyzed in order to 393 
study if the residues involved in their immunogenicity also had an impact in their 394 
receptor binding. Our results show that there was a change in the recognition pattern 395 
between the VA387_1996 and the Den Haag_2006b and Sydney_2012 variants. 396 
While the VA387_1996 strain possessed a high binding ability to the SiLex antigen, 397 
the Den Haag_2006b and Sydney_2012 variants did not recognize any of the assayed 398 
antigens (Figure 9). Interestingly, the M1 incorporating the single mutation Q396R 399 
lost its binding ability to the tested HBAs, showing the same recognition pattern as 400 
the 2006b and 2012 variants. The M2 mutant maintained a similar binding to SiLex as 401 
did the wild type VA387_1996. M3 and M4 increased their recognition ability to 402 
blood group A, B and O antigens. Moreover, M4 recognized the non-functionalized 403 
HSA. Finally, the M5 mutant demonstrated a residual binding of 10% to SiLex.  404 
405 
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DISCUSSION 406 
Due to the relevance of the antibody escape variants in NoV GII.4 persistence during 407 
the last 40 years, we decided to resolve the epitope recognized by the 3C3G3 mAb, 408 
which is a binding blocking antibody. The results of the present study shed light on 409 
how NoV escapes to antibody neutralization. This antibody was not able to recognize 410 
any of the tested antigens by Western Blot, indicating that the target epitope should be 411 
conformational. For this reason, a phage display approach was chosen. Of the eleven 412 
residues suspected to form part of the epitope (see Results) two of them, R397 and 413 
D448, were confirmed to be part of the epitope by site-directed mutagenesis of 414 
VA387_1996 P particles. When different P particles were produced, differences in 415 
electrophoretic mobility were observed. These differences in the electrophoretic 416 
mobility have been previously reported for the VA387 variant and were associated to 417 
P particle formation (P dimers versus P particles) (22) and might reveal structural 418 
changes. In the present study, all the designed P particles were found to be 419 
successfully constructed, with estimated molecular weights ranging from 870 to 1,030 420 
kDa.  421 
Besides the R397 and D448 residues, another difference between VA387_1996 and 422 
Den Haag_2006b sequences was a change involving amino acids 393-395 (STT in the 423 
Den Haag_2006b variant and N-N in the VA387_1996 variant). This change was 424 
incorporated in the M3 and M5 mutants because they were in the close vicinity of 425 
R397. They had been previously described to form an important epitope in GII.4 426 
NoVs (15). Nevertheless, these three residues did not rescue the binding ability of the 427 
3C3G3 antibody (M3 was not recognized by 3C3G3), but they helped stabilizing the 428 
3C3G3 epitope, since 3C3G3 had 6 times more affinity for M5 than for M4. After the 429 
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molecular modeling of the 5 mutants (Figure 6), we could predict the formation of a 430 
saline bridge between R397 and D448 only in M5 and not in M4. That could explain 431 
the higher stability of the 3C3G3 epitope in M5, while the 393-395 STT residues did 432 
not seem to be part of the 3C3G3 epitope themselves. 433 
As shown in Table 4 it seems that residues R397 and D448 have been important in the 434 
successive GII.4 variants. In order to elucidate if they are part of epitopes recognized 435 
by other mAbs raised against different GII.4 variants we also characterized two 436 
previously obtained mAbs, anti-v0.8 and anti-v2.5, that were tested against the same 437 
antigens and mutants as 3C3G3 mAb. We confirmed by ELISA and SPR that the anti-438 
v0.8 was dependent on antigenic site B (393-395 –NN to STT) as previously 439 
described (15). The epitope recognized by anti-v0.8 was also affected in the M1 and 440 
M2 mutants, indicating that amino acids 397 and 448 might also be implicated in the 441 
epitope conformation. Furthermore, the results with all three mAbs showed that there 442 
was only cross reactivity between the closer variants, and that none of the more 443 
distant variants shared any reactivity (Table 3). The anti-v2.5 mAb only recognized 444 
the more closely P particle corresponding to the GII.4 Den Haag_2006b variant. All 445 
the mutants were made using the VA387_1996 variant as scaffold that is not 446 
recognized by this antibody. Only if R397 and D448 were present in its epitope, 447 
recognition by this antibody would be recovered. The only conclusion that we can 448 
obtain is that these residues might not be part of the anti-v2.5 mAb epitope. 449 
These results possess important implications from the evolutionary point of view, 450 
since they demonstrate that the mAbs against the older variants do not recognize the 451 
newer ones. They explain why the same genotype can produce successive pandemics. 452 
Moreover, the HPA-pAb is able to recognize the GI.1 VLPs, but not the GI.1 P 453 
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particles, supporting the idea that the cross-reactive epitopes between both NoV 454 
genogroups are present only in the shell domain of VP1, which is not present in the P 455 
particles (31, 32). 456 
When the 3C3G3 epitope was compared in several NoVs GII.4 variants (Table 4), the 457 
two residues identified in the present study, R397 and D448, were always conserved. 458 
All the variants prior to 2004 possessed the combination Q397-N448, and all the 459 
variants that emerged since 2006 contain the duplet R397-D448. There was a 460 
transition period between 2004 and 2006 where both duplets were present, but always 461 
in the same combination. In the VA387_1996 structure and in the structural models of 462 
Figure 6 it was observed that these two amino acids were located very close to each 463 
other, and in M5 they seemed to interact through a saline bridge. This physical 464 
interaction might explain why these two residues were in fixed combinations 465 
throughout the different variants. We could hypothesize that these residues might 466 
additionally be involved in the stabilization of the P particle itself, not just in the 467 
3C3G3 epitope. Indeed, we observed changes in the electrophoretic mobility of the 468 
different P particles when these residues were mutagenized within the VA387_1996, 469 
M1 and M4 P particles being the most heterogeneous migrating particles. 470 
Nevertheless, the Den Haag_2006b and Sydney_2012 variants, which possess the 471 
R397-D448 pair, along with the 393-395 STT version of the antigenic site B (that 472 
favors the formation of the R397-D448 saline bridge), were more homogenous than 473 
was the 1996 variant. 474 
It is known that GII.4 noroviruses have strain specific HBGAs recognition patterns 475 
(17, 18, 33). To evaluate whether the 3C3G3 epitope was involved in the interaction 476 
with receptors, we analyzed the binding of the different GII.4 P particles to several 477 
HBGAs. Our results indicated that the change in R397 seemed to be the key in the 478 
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different recognition patterns seen in the newer GII.4 variants compared to those of 479 
the older ones. The conclusion reached was that this change might have had an effect 480 
on the folding of the fucose-binding pocket that is not in contact with this residue 481 
(Figure 6).  482 
Interestingly, the M4 mutant that includes both substitutions (Q396R and N447D) has 483 
an exacerbated binding ability including a high binding to the HSA (negative control). 484 
In Table 4 we can observe that this amino acid combination (R396 and D447) is 485 
always accompanied with the antigenic site B triplet and not with the duplet as it is 486 
present in M4. The combination of the antigenic site B duplet with R396 and D447 487 
has not been found in wild-type viruses so far, which may reflect a negative selection 488 
process probably due to its impaired binding, as seen with M4 mutant.  489 
This was the first time that phage display was applied to study GII.4 NoV epitopes. In 490 
previous studies, evolutionary and structural approaches were used to identify 491 
putative epitopes including site A (amino acids 296-298) and B (amino acids 393-492 
395) (16). These epitopes were confirmed using chimeras between different NoV 493 
GII4 variants and monoclonal antibodies (15). A similar approach showed that site A 494 
should be formed by amino acids 294, 368 and 372 in addition to 296-298 (17). It 495 
whas also been shown that epitope B had an influence on the changes in the HBGA 496 
binding abilities of different GII4 variants (17, 18). Using the phage display technique 497 
we have been able to identify two residues (397 and 448) that were not as exposed as 498 
the previously described epitopes, thus making it difficult to predict their relevance 499 
after structural analysis. We have shown that these residues play an important role in 500 
antibody recognition, HBGA interactions, and that they have evolved from ancestral 501 
to modern variants. 502 
 503 
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Altogether, we were able to study the epitope recognized by the 3C3G3 antibody and 504 
have shown that this epitope was implicated in viral host interactions. On the one 505 
hand, the two amino acids, R397 and D448, seemed to be involved in the evasion to 506 
the host antibody response, showing how small changes in the amino acid sequence 507 
could render huge benefits to the virus in terms of antibody evasion. On the other 508 
hand, we have demonstrated that a single change in position 396 of the 1996 variant 509 
(397 of 2006b variant) could be enough to modulate the binding of noroviruses to 510 
HBGAs.  511 
 512 
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Tables and Figure legends 632 
 633 
Table 1. Primers used for site-directed mutagenesis 634 
 635 
Table 2. Neoglycoconjugates used in the present study 636 
Designation Oligosaccharide structure 
H-type 1-HSA Fucα2Galβ3GlcNAcβ3Galβ4Glcc-APD- 
SiLex–HSA Neu5Acα3Galβ4(Fucα3)GlcNAcβ3Galβ4Glcc-APD 
Lex–HSA Galβ4(Fucα3)GlcNAcβ3Galβ4(Fucα3)GlcNAc-APD 
A-tri-HSA GalNAcα3(Fucα2)Galβ−O−APE 
B-tri-HSA  Galα3(Fucα2)Galβ−O−APE 
 637 
 638 
 639 
Primer Sequence Mutant 
MUT_1_FW 5’-CAGGATGGTAATAACCACAGGAATGAACCCCAGCAATG-3’ M1 and M4 
MUT_1_RV 5’- CATTGCTGGGGTTCATTCCTGTGGTTATTACCATCCTG-3’ M1 and M4 
MUT_2_FW 5’- CGGGTATCCCAACATGGACCTGGATTGCCTACTC-3’ M2, M4 and M5 
MUT_2_RV 5’- GAGTAGGCAATCCAGGTCCATGTTGGGATACCCG-3’ M2, M4 and M5 
MUT_3_1_FW 5’- CGTCATCCAGGATGGTAGCACCCACCAAAATGAACCCC-3’ M3 and M5 
MUT_3_1_RV 5’- GGGGTTCATTTTGGTGGGTGCTACCATCCTGGATGACG-3’ M3 and M5 
MUT_3_2_FW 5’- CCAGGATGGTAGCACAACCCACCAAAATGAACC-3’ M3 and M5 
MUT_3_2_RV 5’-GGTCCTACCATCGTGTTGGGTGGTTTTACTTGG-3’ M3 and M5 
MUT_1_3_FW 5’-CGTCATCCAGGATGGTAGCACAACCCACAGGAATGAACCCCAGCAATG-3’ M5 
MUT_1_3_RV 5’-CATTGCTGGGGTTCATTCCTGTGGGTTGTGCTACCATCCTGGATGACG-3’ M5 
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 640 
Table 3. Antibody reactivity against different norovirus antigens by ELISA and 641 
affinity constants (KD) estimated by surface plasmon resonance.   642 
 643 
Norovirus antigen Antibody 
 HPA-pAb P-pAb 3C3G3 mAb Anti-v0.8 mAb Anti-v2.5 mAb 
VLP GI.1 Norwalk + ND - - - 
VLP GII.4-1999 + + - + - 
VLP GII.4-2004 + + - - + 
VLP GII.3 + + - - - 
P-GI.1 Norwalk - ND - - - 
P-GII.4-1996 + + - + (47±35 nM) - 
P-GII.4-1996 M1 + + - + (72±49 nM) - 
P-GII.4-1996 M2 + + - + (7±1 nM) - 
P-GII.4-1996 M3 + + - + (12±3 nM) - 
P-GII.4-1996 M4 + + + (153±74 nM) + (7±1 nM) - 
P-GII.4-1996 M5 + + + (25±12 nM) + (12±3 nM) - 
P-GII.4-2006b + + + (2.1±1 nM) - + (11±3 nM) 
P-GII.4-2012 + + - - - 
P-domain GII.4-2007 + + + - - 
+ = positive recognition; - = negative recognition; ND = not determined. HPA-pAb= rabbit 644 
polyclonal anti-serum raised against GII.4 v0_2000, GII.4 v2_2004 and GII.3 VLPs. P-645 
pAb= rabbit policlonal anti-serum raised against GII.4 VA389_1996 P particles.  646 
 647 
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Table 4. 3C3G3 epitope sequence in different variants of the GII.4 norovirus. 648 
 649 
Norovirus strain (variant) Accession 
number 
Year Amino acid residues of norovirus VP1 (2006b Den Haag) Antigenic 
site B 
245 247 389 390 397 435 443 444 445 446 448 393-395 
3C3G3 epitope   P E I Q R R G Y P N D  
GII.4 MD134-7 (<1996)  AY030098 1987 - - - - Q - - - - - N D - H 
GII.4 Bristi (<1996) X76716 1993 - - - - Q - - - - - N D - H 
GII.4 Kaiso (<1996)  AB294779 2003 - - - - Q - - - - - N D - R 
GII.4 VA387 (1996) AY038600.3 1998 - - - - Q - - - - - N N - N 
GII.4 004 95M-14 (1996) AF080551 1995 - - - - Q - - - - - N N - N 
GII.4 Narita 104 (1996) AB078336 2002 - - - - Q - - - - - N N - N 
GII4 V0 (1999)  1999 - - - - Q -  - - - - N  N - N 
GII.4 Farmington Hills (2002) AY502023 2002 - - V - Q - - - - - N N G T 
GII.4 Oxford B5S22 (2002) AY581254 2003 - - V - Q - - - - - N N G T 
GII.4 Hunter 284E (2004) DQ078794 2004 - - V - - - - - - - - S T T 
GII4 V2 (2004)  2004 - - T - - - - - - - - S T A 
GII.4 Kimitsu (2004) AB294784 2005 - - V - Q - - - - - N S T T 
GII.4 Den Haag 54 (2004) EF126962 2006 - - V - Q - - - - - N S T T 
GII.4 Isumi 060936 (2006a) AB294790 2006 - - V - Q - - - - - N S T T 
GII.4 Yerseke 38 (2006a) EF126963 2006 - - V - Q - - - - - N S T T 
GII.4 Sakai (2006b) AB220922 2005 - - - - Q - - - - - N S S A 
GII.4 NSW696T (2006b) EF684915 2006 - - T - - - - - - - - S T T 
GII.4 Den Haag (2006b)  2006 - - - - - - - - - - - S T T 
GII.4_Apeldoorn (2007)  2007 - - - - - - - - - - - N T A 
GII.4 New Orleans (2009) KR904211 2009 - - - - - - - - - - - G T T 
GII.4 Sydney (2012) AGV76572.1 2012 - - - - - - - - - - - S T T 
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 650 
Figure 1. Alignment of the deduced amino acid residues from GII.4 VA387_1996, 651 
M1 to M5 mutants and the Den Haag_2006b variant. The eleven residues forming the 652 
predicted 3C3G3 epitope are boxed (R397 and D448 in red). 653 
 654 
Figure 2. 12% SDS-PAGE gel stained with Coomassie blue showing the 10 different 655 
P particles used in the present study. The molecular weights are indicated with bars on 656 
the left of the image.  657 
 658 
Figure 3. Chromatograms showing the size exclusion chromatography of GII.4 659 
VA387_1996, M1 to M5 mutants and Den Haag_2006b P particles (panels A to G). 660 
The arrows indicate the elution peak corresponding to P particles with an expected 661 
molecular weight of 840 kDa. The asterisks show the elution peak of non-particulate 662 
proteins. The elution times and calculated molecular weights of each P particle 663 
preparation are indicated in panel H. 664 
 665 
Figure 4. Binding properties of 4 different antibodies: anti-v0.8, anti-v2.5, 3C3G3 666 
and HPA pAb to a panel of norovirus antigens (VLPs, P particles and P domain) 667 
analysed by ELISA. For clarity, only the 1/1,000 dilutions are represented. The error 668 
bars indicate the standard deviation of three replicates. The horizontal line indicates 669 
the cut-off value of the ELISA. 670 
 671 
Figure 5. Blockade of GII.4 Den Haag_2006b P particles binding to a secretor 672 
positive saliva by the 3C3G3 mAb. The error bars indicate the standard deviation of 673 
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three replicates. The numbers in the X axe indicate the concentration of the 3C3G3 674 
mAb.    675 
 676 
Figure 6. Structural models shown in surface of the different mutants produced in the 677 
present study. The P1 subdomain is shown in gray and the P2 in blue. Blood group 678 
trisaccharide type A was located according to PDB id: 2OBS and can be found as a 679 
stick representation. Panel A shows the structure of VA387_1996 wild type with the 680 
residues forming the 3C3G3 epitope in red. Panels B, C and D show the single 681 
mutants M1, M2 and M3, respectively. Panel E shows the model of the double M4 682 
mutant and panel F the model of the M5 multiple mutant. All mutations are shown in 683 
pink. Only mutant M5 has the D448 anionic carboxylate (RCOO−) and R397 cationic 684 
ammonium (RNH3+) in a close conformation that increases the possibility of a saline 685 
bridge formation that allows the 3C3G3 epitope stabilization. 686 
 687 
Figure 7. Binding of different antibodies to wild-type and mutant P particles analysed 688 
by ELISA. Panel A shows the recognition by the P-pAb and 3C3G3 antibodies. Panel 689 
B shows the recognition by anti-v0.8 and anti-v2.5 mAbs. Only the 1/1,000 dilution is 690 
shown for clarity. The error bars indicate the standard deviation of three replicates. 691 
The horizontal line indicates the cut-off value of the ELISA. 692 
 693 
Figure 8. Representation of the different affinity constants (KD) in molar (M) 694 
obtained by surface plasmon resonance experiments. The error bars indicate the 695 
standard deviation of three replicates. The arrow indicates the better interaction pair.  696 
  697 
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Figure 9. Percentages of binding of seven different P particles (VA387-1996, M1 to 698 
M5 and Den Haag_2006b) to five different HBGAs (SiLex antigen, Lex antigen, blood 699 
group A, B and O (H) antigens) determined by ELISA. Each P particle binding was 700 
normalized with the higher OD492 value, and percentages are shown. Error bars 701 
indicate the standard deviations. Human serum albumin (HSA) was used as the 702 
control. 703 
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